8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Feb 25, 2026·SEC
ACADIA Pharmaceuticals Inc.(ACAD)Earnings, Financials & Key Ratios
ACAD•NASDAQ
9.4× P/E·Price updated Jun 19, 2026
AboutACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.Show more
- Revenue$1.07B+11.9%
- EBITDA$139M-43.7%
- Net Income$391M+72.7%
- EPS (Diluted)2.29+68.4%
- Gross Margin91.69%+0.3%
- EBITDA Margin12.96%-49.7%
- Operating Margin9.78%-59.4%
- Net Margin36.49%+54.3%
- ROE39.89%+2.6%
ACAD Key Insights
ACADIA Pharmaceuticals Inc. (ACAD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 21.4%
- ✓Strong 5Y sales CAGR of 19.4%
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ACAD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACAD Price & Volume
ACADIA Pharmaceuticals Inc. (ACAD) stock price & volume — 10-year historical chart
Loading chart...
ACAD Growth Metrics
ACADIA Pharmaceuticals Inc. (ACAD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years165.75%
5 Years19.39%
3 Years27.48%
TTM9.93%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM64.12%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM60.58%
Return on Capital
10 Years-32.59%
5 Years-7.59%
3 Years10.2%
Last Year10.08%
ACAD Recent Earnings
ACADIA Pharmaceuticals Inc. (ACAD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.02-50.0%
$0.04
Rev
$268M-4.3%
$280M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$1.60+1067.9%
$0.14
Rev
$284M-3.0%
$293M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.26+85.7%
$0.14
Rev
$279M-4.8%
$293M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.16+14.3%
$0.14
Rev
$265M+1.0%
$262M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.02vs $0.04-50.0% | $268Mvs $280M-4.3% |
| Q1 2026 | Feb 25, 2026 | $1.60vs $0.14+1067.9% | $284Mvs $293M-3.0% |
| Q4 2025 | Nov 5, 2025 | $0.26vs $0.14+85.7% | $279Mvs $293M-4.8% |
| Q3 2025 | Aug 6, 2025 | $0.16vs $0.14+14.3% | $265Mvs $262M+1.0% |
Based on last 12 quarters of dataView full earnings history →
ACAD Peer Comparison
ACADIA Pharmaceuticals Inc. (ACAD) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INTR | 2.4B | 5.44 | 9.61 | 50.54% | 8.99% | 14.24% | 2.85 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare ACAD vs Peers
ACADIA Pharmaceuticals Inc. (ACAD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACAD Income Statement
ACADIA Pharmaceuticals Inc. (ACAD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 124.9M | 223.81M | 339.08M | 441.75M | 484.14M | 517.24M | 726.44M | 957.8M | 1.07B | 1.1B |
Revenue Growth % | 620.68% | 79.19% | 51.5% | 30.28% | 9.6% | 6.83% | 40.45% | 31.85% | 11.87% | 9.93% |
Cost of Goods Sold | 13.06M | 18.33M | 19.6M | 20.55M | 19.14M | 10.17M | 45.73M | 81.84M | 89M | 93.4M |
COGS % of Revenue | 10.46% | 8.19% | 5.78% | 4.65% | 3.95% | 1.97% | 6.3% | 8.54% | 8.31% | - |
Gross Profit | 111.84M▲ 0% | 205.48M▲ 83.7% | 319.48M▲ 55.5% | 421.2M▲ 31.8% | 465M▲ 10.4% | 507.07M▲ 9.0% | 680.71M▲ 34.2% | 875.96M▲ 28.7% | 982.51M▲ 12.2% | 1B▲ 0% |
Gross Margin % | 89.54% | 91.81% | 94.22% | 95.35% | 96.05% | 98.03% | 93.7% | 91.46% | 91.69% | 91.47% |
Gross Profit Growth % | 765.31% | 83.72% | 55.48% | 31.84% | 10.4% | 9.05% | 34.24% | 28.68% | 12.16% | - |
Operating Expenses | 404.25M | 452.92M | 566.02M | 707.79M | 635.44M | 730.66M | 754.09M | 645.16M | 877.7M | 920.95M |
OpEx % of Revenue | 323.66% | 202.37% | 166.93% | 160.22% | 131.25% | 141.26% | 103.81% | 67.36% | 81.91% | - |
Selling, General & Admin | 255.06M | 265.76M | 325.64M | 388.66M | 396.03M | 369.09M | 402.47M | 488.43M | 548.89M | 593.54M |
SG&A % of Revenue | 204.21% | 118.74% | 96.04% | 87.98% | 81.8% | 71.36% | 55.4% | 50.99% | 51.23% | - |
Research & Development | 149.19M | 187.16M | 240.38M | 319.13M | 239.41M | 361.57M | 351.62M | 303.25M | 328.8M | 327.4M |
R&D % of Revenue | 119.45% | 83.63% | 70.89% | 72.24% | 49.45% | 69.91% | 48.4% | 31.66% | 30.69% | - |
Other Operating Expenses | 3.98M | -1.84M | 0 | 0 | 0 | 0 | 0 | -146.51M | 0 | 0 |
Operating Income | -292.41M▲ 0% | -247.44M▲ 15.4% | -246.54M▲ 0.4% | -286.59M▼ 16.2% | -170.44M▲ 40.5% | -223.6M▼ 31.2% | -73.38M▲ 67.2% | 230.79M▲ 414.5% | 104.81M▼ 54.6% | 80.91M▲ 0% |
Operating Margin % | -234.11% | -110.56% | -72.71% | -64.87% | -35.2% | -43.23% | -10.1% | 24.1% | 9.78% | 7.39% |
Operating Income Growth % | -7.18% | 15.38% | 0.36% | -16.24% | 40.53% | -31.19% | 67.18% | 414.52% | -54.59% | - |
EBITDA | -289.7M | -244.44M | -243.78M | -283.65M | -167.09M | -221.57M | -67.83M | 246.68M | 138.9M | 95.72M |
EBITDA Margin % | -231.94% | -109.22% | -71.9% | -64.21% | -34.51% | -42.84% | -9.34% | 25.75% | 12.96% | 8.74% |
EBITDA Growth % | -6.9% | 15.62% | 0.27% | -16.36% | 41.09% | -32.6% | 69.39% | 463.69% | -43.69% | -61.03% |
D&A (Non-Cash Add-back) | 2.71M | 3M | 2.77M | 2.93M | 3.34M | 2.03M | 5.55M | 15.88M | 0 | 5.88M |
EBIT | -292.41M | -247.44M | -246.54M | -286.59M | -170.44M | -223.6M | -73.38M | 84.28M | 138.9M | 98.67M |
Net Interest Income | 4.13M | 5.35M | 11.16M | 6.61M | 591K | 6.61M | 17.23M | 25.46M | 31.72M | 23.82M |
Interest Income | 4.13M | 5.35M | 11.16M | 6.61M | 591K | 6.61M | 17.23M | 25.46M | 31.72M | 23.82M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 4.13M | 3.51M | 12.16M | 5.61M | 2.92M | 10.15M | 22.34M | 27.28M | 34.09M | 34.2M |
Pretax Income | -288.28M▲ 0% | -243.94M▲ 15.4% | -234.38M▲ 3.9% | -280.97M▼ 19.9% | -167.52M▲ 40.4% | -213.44M▼ 27.4% | -51.04M▲ 76.1% | 258.07M▲ 605.7% | 138.9M▼ 46.2% | 115.11M▲ 0% |
Pretax Margin % | -230.81% | -108.99% | -69.12% | -63.6% | -34.6% | -41.27% | -7.03% | 26.94% | 12.96% | 10.51% |
Income Tax | 1.12M | 1.26M | 876K | 611K | 351K | 2.53M | 10.25M | 31.62M | -252.1M | -260.54M |
Effective Tax Rate % | -0.39% | -0.51% | -0.37% | -0.22% | -0.21% | -1.19% | -20.08% | 12.25% | -181.49% | -226.35% |
Net Income | -289.4M▲ 0% | -245.19M▲ 15.3% | -235.26M▲ 4.1% | -281.58M▼ 19.7% | -167.87M▲ 40.4% | -215.97M▼ 28.7% | -61.29M▲ 71.6% | 226.45M▲ 469.5% | 391M▲ 72.7% | 375.65M▲ 0% |
Net Margin % | -231.71% | -109.56% | -69.38% | -63.74% | -34.67% | -41.76% | -8.44% | 23.64% | 36.49% | 34.3% |
Net Income Growth % | -6.64% | 15.28% | 4.05% | -19.69% | 40.38% | -28.66% | 71.62% | 469.5% | 72.66% | 64.12% |
Net Income (Continuing) | -289.4M | -245.19M | -235.26M | -281.58M | -167.87M | -215.97M | -61.29M | 226.45M | 391M | 375.65M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.36▲ 0% | -1.94▲ 17.8% | -1.60▲ 17.5% | -1.79▼ 11.9% | -1.05▲ 41.3% | -1.34▼ 27.6% | -0.37▲ 72.4% | 1.36▲ 467.6% | 2.29▲ 68.4% | 2.18▲ 0% |
EPS Growth % | -0.85% | 17.8% | 17.53% | -11.88% | 41.34% | -27.62% | 72.39% | 467.57% | 68.38% | 60.58% |
EPS (Basic) | -2.36 | -1.94 | -1.60 | -1.79 | -1.05 | -1.34 | -0.37 | 1.37 | 2.32 | - |
Diluted Shares Outstanding | 122.6M | 126.58M | 147.2M | 157.33M | 160.49M | 161.68M | 163.82M | 166.36M | 171.36M | 172.71M |
Basic Shares Outstanding | 122.6M | 126.58M | 147.2M | 157.33M | 160.49M | 161.68M | 163.82M | 165.72M | 169.34M | 170.52M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ACAD Balance Sheet
ACADIA Pharmaceuticals Inc. (ACAD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 373.48M | 526.11M | 760.25M | 717.62M | 617.82M | 507.94M | 616.13M | 938.32M | 1.06B | 1.1B |
Cash & Short-Term Investments | 341.34M | 473.52M | 697.43M | 631.96M | 520.71M | 416.82M | 438.87M | 755.99M | 819.69M | 851.46M |
Cash Only | 69.42M | 134.76M | 189.68M | 326.03M | 147.44M | 114.85M | 188.66M | 319.59M | 177.69M | 851.46M |
Short-Term Investments | 271.92M | 338.76M | 507.75M | 305.93M | 373.27M | 301.98M | 250.21M | 436.4M | 641.99M | 569.25M |
Accounts Receivable | 18.43M | 27.79M | 37.87M | 50.28M | 65.34M | 63.08M | 102.35M | 104.69M | 148.23M | 135.35M |
Days Sales Outstanding | 53.86 | 45.32 | 40.77 | 41.55 | 49.26 | 44.51 | 51.43 | 39.9 | 50.49 | 45.22 |
Inventory | 5.25M | 4.07M | 6.34M | 9.68M | 7.88M | 6.64M | 35.82M | 21.95M | 34.67M | 31.57M |
Days Inventory Outstanding | 146.67 | 81.04 | 118.1 | 171.97 | 150.28 | 238.26 | 285.89 | 97.89 | 142.19 | 118.67 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77.63M |
Total Non-Current Assets | 11.03M | 14.1M | 22.93M | 65M | 82.3M | 79.88M | 132.83M | 249.44M | 502.08M | 509.21M |
Property, Plant & Equipment | 2.66M | 3.31M | 12.7M | 56.44M | 66.31M | 61.59M | 56.47M | 50.79M | 54.87M | 60.93M |
Fixed Asset Turnover | 46.92x | 67.64x | 26.69x | 7.83x | 7.30x | 8.40x | 12.86x | 18.86x | 19.53x | 19.58x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 5.54M | 4.06M | 2.58M | 1.11M | 0 | 0 | 65.49M | 119.78M | 108.89M | 106.17M |
Long-Term Investments | 2.48M | 4.83M | 7.09M | 7.07M | 0 | 12.97M | 5.77M | 0 | 7.84M | 26.79M |
Other Non-Current Assets | 2.83M | 6.72M | 557K | 378K | 15.98M | 5.31M | 5.1M | 78.87M | 80.6M | 92.49M |
Total Assets | 384.51M▲ 0% | 540.2M▲ 40.5% | 783.18M▲ 45.0% | 782.62M▼ 0.1% | 700.12M▼ 10.5% | 587.81M▼ 16.0% | 748.96M▲ 27.4% | 1.19B▲ 58.6% | 1.56B▲ 31.7% | 1.61B▲ 0% |
Asset Turnover | 0.32x | 0.41x | 0.43x | 0.56x | 0.69x | 0.88x | 0.97x | 0.81x | 0.69x | 0.77x |
Asset Growth % | -31.48% | 40.49% | 44.98% | -0.07% | -10.54% | -16.04% | 27.41% | 58.59% | 31.69% | 143.75% |
Total Current Liabilities | 49.03M | 59.56M | 74.83M | 105.97M | 96.07M | 125.63M | 254.25M | 394.87M | 277.11M | 305.52M |
Accounts Payable | 8.79M | 3.17M | 7.22M | 8.49M | 6.88M | 12.75M | 17.54M | 16.19M | 10.9M | 12.25M |
Days Payables Outstanding | 245.55 | 63.06 | 134.51 | 150.85 | 131.12 | 457.63 | 140.02 | 72.21 | 44.72 | 63.5 |
Short-Term Debt | 0 | 0 | 3.43M | 5.09M | 0 | 0 | 9.4M | 0 | 11.63M | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 21.39M | 33.52M | 31.76M | 52.46M | 25.9M | 49.51M | 92.31M | 36.55M | 254.58M | 293.28M |
Current Ratio | 7.62x | 8.83x | 10.16x | 6.77x | 6.43x | 4.04x | 2.42x | 2.38x | 3.83x | 3.59x |
Quick Ratio | 7.51x | 8.76x | 10.08x | 6.68x | 6.35x | 3.99x | 2.28x | 2.32x | 3.71x | 3.48x |
Cash Conversion Cycle | -45.02 | 63.3 | 24.36 | 62.66 | 68.43 | -174.86 | 197.3 | 65.57 | 147.97 | 100.39 |
Total Non-Current Liabilities | 191K | 1.56M | 9.22M | 49.64M | 63.16M | 61.77M | 62.95M | 60.09M | 59.69M | 51.64M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39M |
Capital Lease Obligations | 0 | 0 | 6.36M | 44.46M | 56.13M | 52.7M | 47.8M | 42.04M | 40.55M | 128.18M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 191K | 1.56M | 2.86M | 5.18M | 7.03M | 9.07M | 15.15M | 18.06M | 19.14M | 12.64M |
Total Liabilities | 49.22M | 61.12M | 84.05M | 155.61M | 159.23M | 187.4M | 317.2M | 454.96M | 336.81M | 357.16M |
Total Debt | 0 | 0 | 9.79M | 49.55M | 64.43M | 62M | 57.2M | 51.99M | 52.19M | 39M |
Net Debt | -69.42M | -134.76M | -179.88M | -276.48M | -83M | -52.85M | -131.45M | -267.59M | -125.51M | -812.46M |
Debt / Equity | - | - | 0.01x | 0.08x | 0.12x | 0.15x | 0.13x | 0.07x | 0.04x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | 0.21x | 0.38x | 0.41x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -1.08x | -0.90x | -8.49x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 335.29M▲ 0% | 479.08M▲ 42.9% | 699.13M▲ 45.9% | 627.01M▼ 10.3% | 540.89M▼ 13.7% | 400.41M▼ 26.0% | 431.75M▲ 7.8% | 732.79M▲ 69.7% | 1.23B▲ 67.5% | 1.25B▲ 0% |
Equity Growth % | -35.32% | 42.89% | 45.93% | -10.32% | -13.73% | -25.97% | 7.83% | 69.72% | 67.49% | 248.67% |
Book Value per Share | 2.73 | 3.78 | 4.75 | 3.99 | 3.37 | 2.48 | 2.64 | 4.40 | 7.16 | 7.23 |
Total Shareholders' Equity | 335.29M | 479.08M | 699.13M | 627.01M | 540.89M | 400.41M | 431.75M | 732.79M | 1.23B | 1.25B |
Common Stock | 12K | 14K | 15K | 16K | 16K | 16K | 16K | 16K | 16K | 16K |
Retained Earnings | -1.22B | -1.47B | -1.7B | -1.99B | -2.15B | -2.37B | -2.43B | -2.2B | -1.81B | -1.81B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -399K | -372K | 297K | 36K | -192K | -975K | 24K | 292K | 1.45M | -563K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACAD Cash Flow Statement
ACADIA Pharmaceuticals Inc. (ACAD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -217.86M | -167.47M | -151.13M | -136.17M | -125.66M | -114.03M | 16.7M | 157.72M | 109.84M | 123.49M |
Operating CF Margin % | -174.42% | -74.83% | -44.57% | -30.82% | -25.96% | -22.05% | 2.3% | 16.47% | 10.25% | - |
Operating CF Growth % | -3.54% | 23.13% | 9.76% | 9.9% | 7.72% | 9.25% | 114.65% | 844.31% | -30.36% | 19.68% |
Net Income | -289.4M | -245.19M | -235.26M | -281.58M | -167.87M | -215.97M | -61.29M | 226.45M | 391M | 375.65M |
Depreciation & Amortization | 2.71M | 3M | 2.77M | 2.93M | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M | 7.71M |
Stock-Based Compensation | 75.53M | 81.56M | 82.27M | 84.42M | 63.62M | 68.2M | 66.42M | 67.05M | 0 | 27.52M |
Deferred Taxes | 0 | 0 | 0 | 2.75M | 0 | 0 | 0 | 0 | -249.88M | -249.97M |
Other Non-Cash Items | -287K | 1.35M | -4.61M | 44.28M | 75K | -6.28M | -12.12M | -155.82M | 46.71M | 28.27M |
Working Capital Changes | -6.41M | -8.2M | 3.71M | 11.04M | -24.82M | 37.99M | 18.13M | 4.16M | -89.76M | -65.68M |
Change in Receivables | -11.44M | -8.75M | -9.69M | -12.47M | -16.12M | 2.26M | -39.27M | -2.35M | -43.54M | -34.67M |
Change in Inventory | -1.01M | 1.93M | -1.74M | -3.32M | -4.21M | 2.42M | -28.81M | -49.55M | -18.2M | -7.67M |
Change in Payables | 4.87M | -5.62M | 4.05M | 1.27M | -1.62M | 5.87M | 4.8M | -1.35M | -5.29M | -5.85M |
Cash from Investing | 92.47M | -71.49M | -165.84M | 192.51M | -71.1M | 73.24M | 32M | -30.54M | -302.56M | -112.23M |
Capital Expenditures | -812K | -2.15M | -1.13M | -7.59M | -1.12M | 0 | -40.05M | -523K | -103.53M | 88.94M |
CapEx % of Revenue | 0.65% | 0.96% | 0.33% | 1.72% | 0.23% | - | 5.51% | 0.05% | 9.66% | 8.12% |
Acquisitions | 0 | 44K | 164.71M | -200.1M | 69.98M | 0 | -32.05M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 93.28M | 44K | -164.71M | 200.1M | -69.98M | 0 | 32.05M | 146.51M | 0 | -98.84M |
Cash from Financing | 31.19M | 306.65M | 371.85M | 81M | 18.16M | 8.2M | 25.13M | 6.84M | 49.88M | 52.28M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 31.19M | 306.65M | 371.85M | 81M | 18.16M | 8.2M | 25.13M | 6.84M | 49.88M | 52.28M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | -94.2M▲ 0% | 67.69M▲ 171.9% | 54.88M▼ 18.9% | 137.33M▲ 150.2% | -178.59M▼ 230.0% | -32.59M▲ 81.8% | 73.81M▲ 326.5% | 133.93M▲ 81.5% | -141.89M▼ 205.9% | 65.22M▲ 0% |
Free Cash Flow | -218.67M▲ 0% | -169.62M▲ 22.4% | -152.26M▲ 10.2% | -143.75M▲ 5.6% | -126.78M▲ 11.8% | -114.03M▲ 10.1% | -23.35M▲ 79.5% | 157.2M▲ 773.3% | 105.15M▼ 33.1% | 212.43M▲ 0% |
FCF Margin % | -175.07% | -75.79% | -44.9% | -32.54% | -26.19% | -22.05% | -3.21% | 16.41% | 9.81% | 19.4% |
FCF Growth % | 0.57% | 22.43% | 10.23% | 5.59% | 11.81% | 10.05% | 79.53% | 773.27% | -33.11% | 328.27% |
FCF per Share | -1.78 | -1.34 | -1.03 | -0.91 | -0.79 | -0.71 | -0.14 | 0.94 | 0.61 | 1.23 |
FCF Conversion (FCF/Net Income) | 0.75x | 0.68x | 0.64x | 0.48x | 0.75x | 0.53x | -0.27x | 0.70x | 0.28x | 0.57x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 1.37M | 1.26M | 1.6M | 1.11M | 1.04M | 2.19M | 5.85M | 19.52M | 0 | 0 |
ACAD Key Ratios
ACADIA Pharmaceuticals Inc. (ACAD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -67.8% | -60.22% | -39.93% | -42.47% | -28.75% | -45.89% | -14.73% | 38.89% | 39.89% | 35.65% |
Return on Invested Capital (ROIC) | -70.67% | -60.83% | -42.82% | -49.42% | -31.62% | -41.64% | -16.99% | 45.22% | 10.03% | 8.44% |
Gross Margin | 89.54% | 91.81% | 94.22% | 95.35% | 96.05% | 98.03% | 93.7% | 91.46% | 91.69% | 91.47% |
Net Margin | -231.71% | -109.56% | -69.38% | -63.74% | -34.67% | -41.76% | -8.44% | 23.64% | 36.49% | 34.3% |
Debt / Equity | - | - | 0.01x | 0.08x | 0.12x | 0.15x | 0.13x | 0.07x | 0.04x | 0.03x |
FCF Conversion | 0.75x | 0.68x | 0.64x | 0.48x | 0.75x | 0.53x | -0.27x | 0.70x | 0.28x | 0.57x |
Revenue Growth | 620.68% | 79.19% | 51.5% | 30.28% | 9.6% | 6.83% | 40.45% | 31.85% | 11.87% | 9.93% |
Related:ACAD Dividend History·ACAD Revenue History·ACAD Price History·ACAD P/E History·ACAD Financial Ratios·ACAD Institutional Holders
ACAD SEC Filings & Documents
ACADIA Pharmaceuticals Inc. (ACAD) SEC filings — annual & quarterly reports (10-K, 10-Q)
ACAD Frequently Asked Questions
ACADIA Pharmaceuticals Inc. (ACAD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ACADIA Pharmaceuticals Inc. (ACAD) reported $1.10B in revenue for fiscal year 2025. This represents a 25300% increase from $4.3M in 2000.
ACADIA Pharmaceuticals Inc. (ACAD) grew revenue by 11.9% over the past year. This is steady growth.
Yes, ACADIA Pharmaceuticals Inc. (ACAD) is profitable, generating $375.6M in net income for fiscal year 2025 (36.5% net margin).
Dividend & Returns
ACADIA Pharmaceuticals Inc. (ACAD) has a return on equity (ROE) of 39.9%. This is excellent, indicating efficient use of shareholder capital.
ACADIA Pharmaceuticals Inc. (ACAD) generated $212.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.